Latest News
What Happens After a Digital Mental Health Screening Result
A self-assessment can identify symptoms, but the value of mental health screening depends on what people understand, choose and can access after seeing the result. A person completes an online mental health questionnaire and receives a score suggesting that...
Latest News
Weekly News Roundup | 26 October 2026
Life science news 26 October 2026: two major deals, three US approvals, two UK updates and a reverse merger. Roche signed an antibody-drug conjugate deal with Hansoh. Merck KGaA agreed to buy Silence Therapeutics for about $1.3bn. The FDA granted accelerated approval...
Melanoma Vaccine Approval: When Could Intismeran Reach Patients?
Melanoma vaccine approval has not happened yet. No regulator has approved intismeran autogene, and its developers have not announced a filing date. On 22 October 2026, Merck and Moderna released detailed phase 3 data. They said they are engaging with regulatory...
Exosomes Move Toward the Mainstream. Manufacturing May Be the Key to Scale
For much of the past decade, exosomes have occupied a familiar place in biotechnology: scientifically intriguing, biologically versatile and full of potential, but still some distance from becoming routinely manufactured products. That is beginning to change as...
From Regulation to Adoption: What Europe Needs Next for AI in Health
The UK and EU have reached a pivotal point in the regulation of AI in health. Both have set ambitious goals for protecting patients while enabling innovation, but success will depend on whether regulatory frameworks can be translated into responsible adoption and...
Join The Future Of Life Sciences Media
In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.
Don’t wait for the media to pick up your story. Be the media.
Trending
More News
The New Launch Model for the Agentic Era
Creating brand value when clinical information is no longer a differentiator The Life Sciences industry is undergoing seismic shifts: expanding drug pipelines, compressed launch timelines, and changing healthcare provider (HCP) and human capital expectations. HCPs...
Britain’s Nicotine Pouch Problem: What It Means for Oral Health
The UK Government has taken steps to combat smoking, and now nicotine pouches, through legislation, public health campaigns, youth prevention and support services. In the UK the age limit for smoking is 18 years old, meaning that individuals must be at least 18 to buy...
FUS-ALS Treatment Clears Phase 3 but the Figures Stay Unpublished
Ionis Pharmaceuticals and Otsuka Pharmaceutical reported positive topline results on 22 September 2026 from the Phase 3 FUSION study. The trial tested ulefnersen in amyotrophic lateral sclerosis caused by mutations in the fused in sarcoma gene. Ionis describes the...
Why Business Fundamentals Belong in Every Life Sciences Career
As a life scientist you might not have considered a business education. You are good at what you do, you may have no ambition to run a company or sit at a boardroom table. So why spend time on business fundamentals? The honest answer is that deep technical expertise...
Telix Buys ITM: Radioisotope Supply and a Manufacturing Test
Telix Pharmaceuticals has agreed to buy ITM Isotope Technologies Munich SE. Telix describes ITM as the largest supplier of lutetium-177 by revenue. The deal places that radioisotope supply business inside a therapeutics developer. Telix issued the joint announcement...
LNP Engineering for RNA Delivery: Beyond Encapsulation Efficiency
For RNA therapeutics, encapsulation efficiency is a formulation metric—not proof of functional delivery. The development of lipid nanoparticle (LNP) RNA delivery systems is entering a more demanding phase. As nucleic acid therapeutics expand beyond conventional siRNA...
Closing the Gap: Why Where You Live Still Determines Your IBD Care
Inflammatory bowel disease (IBD) is no longer a rare disease in Australia. Close to 180,000 Australians are now living with Crohn’s disease or ulcerative colitis, with prevalence approaching 1% of the population in some estimates. Unlike many chronic diseases, IBD...
How GLP-1 Drugs Are Reshaping Anesthesia Practice
Few classes of medications have changed the perioperative conversation as quickly as glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Originally developed primarily for the management of type 2 diabetes, GLP-1 therapy is now widely used for obesity and metabolic...
Designing Resilient Health Systems That Endure
The most resilient health systems are not the ones that respond best in times of disruption, they’re the ones designed so that when disruption occurs, care continues and communities remain protected. Systems continue to struggle with workforce shortages, delayed care,...
Weekly News Roundup | 21 September 2026
Life science news 21 September 2026: first US Sanfilippo approval, DESTINY-Lung04 data and a NICE OCD consultation. The FDA approved Fayuvi, the first treatment for Sanfilippo syndrome type A. AstraZeneca and Daiichi Sankyo’s Enhertu cut the risk of lung cancer...
Vivan Therapeutics and Ad Atomica Announce Discovery Collaboration
Partnership pairs Vivan's genotype resolved cancer screening data with Ad Atomica's AI driven molecule design platform LONDON, UK, 16 September 2026: Vivan Therapeutics and Ad Atomica today announced a discovery collaboration. Vivan tests thousands of drugs and drug...
Azetukalner NDA Filed as Xenon Pauses Depression Trials
Xenon Pharmaceuticals submitted the azetukalner NDA to the US Food and Drug Administration on 17 September 2026. The filing covers focal seizures in epilepsy. The same announcement disclosed a voluntary pause on new enrolment in the company’s depression studies. Xenon...
The New Launch Model for the Agentic Era
Creating brand value when clinical information is no longer a differentiator The Life Sciences industry is undergoing seismic shifts: expanding drug pipelines, compressed launch timelines, and changing healthcare provider (HCP) and human capital expectations. HCPs...
Britain’s Nicotine Pouch Problem: What It Means for Oral Health
The UK Government has taken steps to combat smoking, and now nicotine pouches, through legislation, public health campaigns, youth prevention and support services. In the UK the age limit for smoking is 18 years old, meaning that individuals must be at least 18 to buy...
FUS-ALS Treatment Clears Phase 3 but the Figures Stay Unpublished
Ionis Pharmaceuticals and Otsuka Pharmaceutical reported positive topline results on 22 September 2026 from the Phase 3 FUSION study. The trial tested ulefnersen in amyotrophic lateral sclerosis caused by mutations in the fused in sarcoma gene. Ionis describes the...
Why Business Fundamentals Belong in Every Life Sciences Career
As a life scientist you might not have considered a business education. You are good at what you do, you may have no ambition to run a company or sit at a boardroom table. So why spend time on business fundamentals? The honest answer is that deep technical expertise...
Telix Buys ITM: Radioisotope Supply and a Manufacturing Test
Telix Pharmaceuticals has agreed to buy ITM Isotope Technologies Munich SE. Telix describes ITM as the largest supplier of lutetium-177 by revenue. The deal places that radioisotope supply business inside a therapeutics developer. Telix issued the joint announcement...
LNP Engineering for RNA Delivery: Beyond Encapsulation Efficiency
For RNA therapeutics, encapsulation efficiency is a formulation metric—not proof of functional delivery. The development of lipid nanoparticle (LNP) RNA delivery systems is entering a more demanding phase. As nucleic acid therapeutics expand beyond conventional siRNA...
Closing the Gap: Why Where You Live Still Determines Your IBD Care
Inflammatory bowel disease (IBD) is no longer a rare disease in Australia. Close to 180,000 Australians are now living with Crohn’s disease or ulcerative colitis, with prevalence approaching 1% of the population in some estimates. Unlike many chronic diseases, IBD...
How GLP-1 Drugs Are Reshaping Anesthesia Practice
Few classes of medications have changed the perioperative conversation as quickly as glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Originally developed primarily for the management of type 2 diabetes, GLP-1 therapy is now widely used for obesity and metabolic...
Designing Resilient Health Systems That Endure
The most resilient health systems are not the ones that respond best in times of disruption, they’re the ones designed so that when disruption occurs, care continues and communities remain protected. Systems continue to struggle with workforce shortages, delayed care,...
Weekly News Roundup | 21 September 2026
Life science news 21 September 2026: first US Sanfilippo approval, DESTINY-Lung04 data and a NICE OCD consultation. The FDA approved Fayuvi, the first treatment for Sanfilippo syndrome type A. AstraZeneca and Daiichi Sankyo’s Enhertu cut the risk of lung cancer...
Vivan Therapeutics and Ad Atomica Announce Discovery Collaboration
Partnership pairs Vivan's genotype resolved cancer screening data with Ad Atomica's AI driven molecule design platform LONDON, UK, 16 September 2026: Vivan Therapeutics and Ad Atomica today announced a discovery collaboration. Vivan tests thousands of drugs and drug...
Azetukalner NDA Filed as Xenon Pauses Depression Trials
Xenon Pharmaceuticals submitted the azetukalner NDA to the US Food and Drug Administration on 17 September 2026. The filing covers focal seizures in epilepsy. The same announcement disclosed a voluntary pause on new enrolment in the company’s depression studies. Xenon...
Featured Articles
Further News
Metal Medical Device Quality Control: Why Dimensions Are Not Enough
A correct dimension does not guarantee a safe device Metal device quality control should translate clinical and engineering risks into measurable attributes. A machined component can match its drawing, look clean and pass inspection while still carrying a material,...
Healthcare Innovation Is Not Always About Something New
Healthcare innovation is often associated with something new. A new technology. A new platform. A new device. A new digital service. But healthcare organizations do not always need to add something new to improve care. Sometimes, they need to change something that is...
Clinical Trials Roundup | 18 Sept 2026
Definium Therapeutics’ DT120 meets its primary endpoint in the Phase 3 Panorama study in generalised anxiety disorder, AstraZeneca’s camizestrant misses its primary endpoint in the Phase III SERENA-4 study in first-line breast cancer, Vera Therapeutics’ atacicept cuts...
Trutakna Two-Year Data Sharpen the IgAN Full Approval Race
Vera Therapeutics has put a two-year kidney function dataset behind its bid for IgAN full approval. On 15 September 2026, the company reported the final efficacy analysis of the Phase 3 ORIGIN 3 trial. The trial tested Trutakna (atacicept-vymj) in adults with primary...
Digital Health and the Reordering of Life Sciences Commercialization
It’s been an extraordinary two years for anyone working in pharma commercialization, with the macro environment shifting meaningfully under the feet of all those sitting on the commercial side of pharma or building in digital health with pharma partnership...
From Data to Decisions: The Next Frontier in Diabetic Foot Care
If you are not aware of the statistics on diabetic limb loss, they deserve your attention. Prevention is an absolute necessity. We call this diabetic foot care, and the way podiatrists utilize these opportunities is moving into a more data-rich era. Remote...
Expedited IND Pilot Opens as UK Fast Track Bars First-in-Human
The US Food and Drug Administration began accepting applications on 15 September 2026 for its expedited IND pilot. The programme is a key component of Operation TrialBlazer, according to the agency. The Department of Health and Human Services announced that initiative...
Why Pharmaceutical Quality Cannot Be Tested Into a Product
In pharmaceutical manufacturing, quality control testing is often the point at which a product gets its final analytical assessment. But from my experience in pharmaceutical quality control, one principle is worth emphasizing: QC testing is essential, but QC testing...
Fifty Patients, No Registry: MVA Research Meets in London
Mosaic variegated aneuploidy (MVA) is thought to affect fewer than 50 people worldwide. At that scale, ultra-rare disease research runs into a problem that funding alone does not solve. There is no cohort large enough to randomise. There is often no natural history...
Semaglutide Patent Expiry: What Generics Did to Prices
The semaglutide patent expiry of March 2026 has now had six months to work. The evidence is uneven. In India, prices fell by up to 70% within weeks. In Canada, generic pens reached pharmacies in May. In China, not one generic has been approved. Readers in the United...
AI as a Research Partner for the Overstretched Life Sciences
Generative AI can lift the administrative weight of literature reviews and manuscript drafting, but only when it stays grounded in evidence and firmly under human control. The problem we know too well Every clinician who also publishes lives with a quiet collision. On...
FDA Clears First Glioma PET Imaging Drug After 2025 Rejection
The Food and Drug Administration has approved Pixclara, a glioma PET imaging drug from Telix Pharmaceuticals. Telix announced the decision in its approval announcement on 14 September 2026. The active ingredient is floretyrosine F 18, also written as 18F-FET. Telix...
Further News
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.
Don’t wait for the media to pick up your story. Be the media.
See More Articles
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.